PT - JOURNAL ARTICLE AU - Wilfredo F. Garcia-Beltran AU - Kerri J. St. Denis AU - Angelique Hoelzemer AU - Evan C. Lam AU - Adam D. Nitido AU - Maegan L. Sheehan AU - Cristhian Berrios AU - Onosereme Ofoman AU - Christina C. Chang AU - Blake M. Hauser AU - Jared Feldman AU - David J. Gregory AU - Mark C. Poznansky AU - Aaron G. Schmidt AU - A. John Iafrate AU - Vivek Naranbhai AU - Alejandro B. Balazs TI - mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant AID - 10.1101/2021.12.14.21267755 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.14.21267755 4099 - http://medrxiv.org/content/early/2021/12/14/2021.12.14.21267755.short 4100 - http://medrxiv.org/content/early/2021/12/14/2021.12.14.21267755.full AB - Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.1/B.1.1.529) harboring up to 36 mutations in spike protein, the target of vaccine-induced neutralizing antibodies. Given its potential to escape vaccine-induced humoral immunity, we measured neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.COV2.S vaccine recipients against wild type, Delta, and Omicron SARS-CoV-2 pseudoviruses. We included individuals that were vaccinated recently (<3 months), distantly (6-12 months), or recently boosted, and accounted for prior SARS-CoV-2 infection. Remarkably, neutralization of Omicron was undetectable in most vaccinated individuals. However, individuals boosted with mRNA vaccines exhibited potent neutralization of Omicron only 4-6-fold lower than wild type, suggesting that boosters enhance the cross-reactivity of neutralizing antibody responses. In addition, we find Omicron pseudovirus is more infectious than any other variant tested. Overall, this study highlights the importance of boosters to broaden neutralizing antibody responses against highly divergent SARS-CoV-2 variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Institutes of Health, the VIC Innovation fund, the Massachusetts Consortium on Pathogenesis Readiness, the German Center for Infection Research, the Peter and Ann Lambertus Family Foundation, the Medscape Young Investigators Lung Cancer Award, and the MGH Transformative Scholars Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Massachusetts General Brigham gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript